Last updated on April 20, 2014 at 8:28 EDT

Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

August 7, 2012

QUÉBEC CITY, Aug. 7, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the ”Company”) today announced that the United States
Patent and Trademark Office has granted a patent for the use of its
oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult
growth hormone deficiency (AGHD). Filed on February 19, 2007, the
patent (US 8,192,719 B2) titled, “Methods and Kits to Diagnose Growth Hormone Deficiency by Oral
Administration of EP1572 or EP1573 Compounds
“, became effective as of June 5, 2012, and will expire on October 12,
2027. The corresponding composition of matter patent (US 6,861,409 B2),
filed on June 13, 2001 and granted on March 1, 2005, will expire on
August 1, 2022, with the possibility of a patent term extension of up
to 5 years.

Juergen Engel, PhD, President and CEO of Aeterna Zentaris stated, “This
patent, along with our recent Fast Track designation request, represent
important steps in our strategy aimed at bringing AEZS-130 to market in
the most favorable conditions. There is no approved diagnostic test for
AGHD in North America, and we believe AEZS-130 could provide a safe,
effective and convenient oral test for this indication.”

About AGHD

AGHD affects 35,000 adult Americans, with 6,000 new adult patients
diagnosed each year. Growth hormone not only plays an important role in
growth from childhood to adulthood, but helps promote good health
throughout life. AGHD is usually characterized by low energy levels,
decreased strength and exercise tolerance, increased weight or
difficulty losing weight, emotional changes, anxiety and impaired

About AEZS-130

AEZS-130, a ghrelin agonist, is a novel orally-active small molecule
that stimulates the secretion of growth hormone. The Company has
completed a Phase 3 trial for use as an oral diagnostic test for AGHD.
AEZS-130 has been granted orphan drug designation by the FDA for use in
this indication. AEZS-130 is also in a Phase 2A trial as a treatment
for cancer-induced cachexia. Aeterna Zentaris owns the worldwide rights
to AEZS-130.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company’s pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company’s actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors should
consult the Company’s quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company
does not undertake to update these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, unless required to do so by a governmental authority or
by applicable law.


Source: PR Newswire